The inoculum effect of Escherichia coli expressing mcr-1 or not on colistin activity in a murine model of peritonitis.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 14 04 2019
revised: 05 08 2019
accepted: 27 08 2019
pubmed: 9 9 2019
medline: 26 3 2020
entrez: 9 9 2019
Statut: ppublish

Résumé

Colistin often remains the last resort antibiotic active against carbapenemase-producing Enterobacteriaceae. However, while in vitro inoculum effect has been reported, therapeutic relevance of this phenomenon remains questioned. Ten E. coli strains were used that included the wild-type CFT073 and its transconjugant CFT073-MCR-1 and eight susceptible clinical isolates. Mice with peritonitis were treated for 24 h with colistin sulfate. Bacterial loads were determined in peritoneal fluid (PF) and spleen and colistin-resistant mutants were detected. MICs of colistin against the eight susceptible clinical strains and CFT073 ranged from 0.125 to 0.5 mg/L with an inoculum of 10 Phenotypic colistin resistance in wild-type E. coli due to an increase in inoculum size had a therapeutic impact in mice with peritonitis that was comparable to that observed when the mcr-1 gene was expressed.

Identifiants

pubmed: 31494253
pii: S1198-743X(19)30484-7
doi: 10.1016/j.cmi.2019.08.021
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Escherichia coli Proteins 0
MCR-1 protein, E coli 0
Colistin Z67X93HJG1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1563.e5-1563.e8

Informations de copyright

Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

B Fantin (B)

IAME, INSERM UMR 1137, F-75018, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, F-75018, Paris, France; AP-HP, Groupe Hospitalier Paris Nord Val de Seine, Service de médecine interne, F-92210, Clichy, France. Electronic address: bruno.fantin@aphp.fr.

J Poujade (J)

IAME, INSERM UMR 1137, F-75018, Paris, France.

N Grégoire (N)

University of Poitiers, School of Medicine and Pharmacy, INSERM UMR1070, France.

F Chau (F)

IAME, INSERM UMR 1137, F-75018, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, F-75018, Paris, France.

A Roujansky (A)

IAME, INSERM UMR 1137, F-75018, Paris, France.

N Kieffer (N)

Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, INSERM European Unit (LEA, IAME), University of Fribourg, Switzerland.

M Berleur (M)

IAME, INSERM UMR 1137, F-75018, Paris, France.

W Couet (W)

University of Poitiers, School of Medicine and Pharmacy, INSERM UMR1070, France.

P Nordmann (P)

IAME, INSERM UMR 1137, F-75018, Paris, France; Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, INSERM European Unit (LEA, IAME), University of Fribourg, Switzerland; University Hospital and University of Lausanne, Lausanne, Switzerland.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH